AlphaQuest LLC Purchases 14,950 Shares of BioMarin Pharmaceutical Inc. $BMRN

AlphaQuest LLC increased its position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 145.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,261 shares of the biotechnology company’s stock after buying an additional 14,950 shares during the quarter. AlphaQuest LLC’s holdings in BioMarin Pharmaceutical were worth $1,786,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its position in BioMarin Pharmaceutical by 95.9% in the 1st quarter. Farther Finance Advisors LLC now owns 431 shares of the biotechnology company’s stock worth $29,000 after buying an additional 211 shares during the last quarter. LRI Investments LLC lifted its position in BioMarin Pharmaceutical by 856.9% in the 4th quarter. LRI Investments LLC now owns 488 shares of the biotechnology company’s stock worth $32,000 after buying an additional 437 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its position in BioMarin Pharmaceutical by 71.2% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 524 shares of the biotechnology company’s stock worth $37,000 after buying an additional 218 shares during the last quarter. Brooklyn Investment Group lifted its position in BioMarin Pharmaceutical by 2,250.0% in the 1st quarter. Brooklyn Investment Group now owns 564 shares of the biotechnology company’s stock worth $40,000 after buying an additional 540 shares during the last quarter. Finally, Vermillion & White Wealth Management Group LLC bought a new stake in BioMarin Pharmaceutical in the 4th quarter worth approximately $62,000. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

Shares of BioMarin Pharmaceutical stock opened at $58.58 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.56 and a quick ratio of 3.60. The business’s 50 day simple moving average is $57.49 and its two-hundred day simple moving average is $61.39. The stock has a market capitalization of $11.25 billion, a P/E ratio of 17.38, a price-to-earnings-growth ratio of 0.74 and a beta of 0.18. BioMarin Pharmaceutical Inc. has a one year low of $52.93 and a one year high of $93.04.

Analyst Ratings Changes

A number of research firms recently weighed in on BMRN. The Goldman Sachs Group dropped their target price on BioMarin Pharmaceutical from $124.00 to $104.00 and set a “buy” rating for the company in a research report on Monday, May 5th. Wedbush restated an “outperform” rating and issued a $94.00 target price on shares of BioMarin Pharmaceutical in a research report on Tuesday, August 5th. Guggenheim lifted their price target on BioMarin Pharmaceutical from $101.00 to $106.00 and gave the stock a “buy” rating in a research note on Wednesday, August 6th. Morgan Stanley decreased their price target on BioMarin Pharmaceutical from $97.00 to $96.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 22nd. Finally, UBS Group lifted their price target on BioMarin Pharmaceutical from $113.00 to $114.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Eighteen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.17.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.